肝硬化38岁的孟加拉人替诺治疗后表面抗原血清学转换,肝硬

StephenW

Regression of Cirrhosis After HBsAg Seroconversion in a Cirrhotic 38 Year-Old Bangladeshi Man Treated with Tenofovir Disoproxil Fumarate
肝硬化38岁的孟加拉人替诺
治疗后表面抗原血清学转换,肝硬化消退
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), June 2013, Singapore

A Moore1, S Moon2, R Manch1
1Saint Joseph's Hospital and Medical Center, Phoenix, AZ, USA; 2Gilead Sciences, Foster City, CA, USA
CONCLUSIONS

• Dramatic regression of cirrhosis, and seroconversion of both HBeAg and HBsAg were achieved in this Bangladeshi patient with well-compensated cirrhosis while on tenofovir DF therapy.

• Mild steatosis is one possible explanation for persistently elevated ALT despite long-term suppression of HBV DNA and HBsAg seroconversion.

• Further data are needed to guide the decision on when to stop therapy in cirrhotic patients who seroconvert to HBsAb.
戏剧性的回归肝硬化，HBeAg和乙肝表面抗原的血清学转换，实现在孟加拉病人代偿期肝硬化，而​​替诺福韦治疗。

•轻度脂肪肝ALT持续升高的一个可能的解释是，尽管长期抑制HBV DNA和HBsAg血清学转换。

•都需要进一步的数据来指导决定何时停止治疗的肝硬化患者血清转化乙肝表面抗体。

StephenW

StephenW

StephenW

希望奇迹

替诺比恩替效果好？

StephenW

回复 希望奇迹 的帖子

32岁
2006年 G 2/4 S 4/4（肝硬化），阿德福韦治疗, 达到HBVDNA<100拷贝/ ml，ALT升高（脂肪肝）
1/2009 停止Adevfovir
3/2009 HBVDNA 440,000拷贝/ ml，变成大三阳
3/2009 开始替诺福韦
1/2010 HBVDNA<20 IU/毫升，大三阳变成阴性，HBeAb出现
6/2011 乙肝表面抗原转阴
1/2012 乙肝表面抗体44 IU /毫升
4/2012 乙肝表面抗体430 IU /毫升，谷丙转氨酶54，HBVDNA检测不到
2012 活检 G 1/4  S 0/4轻度脂肪肝，继续泰诺福韦